- Home
- BNTX vs DKNG Comparison
BNTX vs DKNG Comparison
Compare BNTX & DKNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNTX | DKNG |
|---|---|---|
| Founded | 2008 | N/A |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8B | 23.8B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | BNTX | DKNG |
|---|---|---|
| Price | $96.21 | $33.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 28 |
| Target Price | ★ $137.40 | $47.71 |
| AVG Volume (30 Days) | 1.1M | ★ 17.9M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,698,814,972.00 | ★ $5,458,104,000.00 |
| Revenue This Year | N/A | $33.29 |
| Revenue Next Year | $9.49 | $20.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.70 | ★ 18.50 |
| 52 Week Low | $81.20 | $26.23 |
| 52 Week High | $129.27 | $53.61 |
Technical Indicators
Market Signals| Indicator | BNTX | DKNG |
|---|---|---|
| Relative Strength Index (RSI) | 38.91 | 60.64 |
| Support Level | $94.00 | $29.09 |
| Resistance Level | $104.05 | $34.29 |
| Average True Range (ATR) | 3.41 | 1.35 |
| MACD | -0.46 | 0.80 |
| Stochastic Oscillator | 11.26 | 93.41 |
Price Performance
Historical ComparisonAbout BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
About DKNG DraftKings Inc.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number two or three revenue share position across states in which it competes. DraftKings is now live with online or retail sports betting in 28 states and iGaming in five states, with both products available to around 40% of Canada's population. In 2024, sports revenue was 61% of total sales, i-gaming 32%, and fantasy and lottery 7%. The company also operates a non-fungible token commissioned-based marketplace and develops and licenses online gaming products.